Friday 24 February 2023

Medidata senior leadership structure powers smarter treatments, healthier people

KUALA LUMPUR, Feb 22 (Bernama) -- Medidata, a Dassault Systèmes company, has announced a new leadership structure designed to fuel its mission of creating end-to-end solutions that power smarter treatments and healthier people.

The strategic evolution is an opportunity to further long-term goals and growth to enhance customers’ ability to unlock greater value across the Dassault Systèmes portfolio, ultimately taking drug development to new heights.

Pascal Daloz, an accomplished leader at Dassault Systèmes, was named Chief Executive Officer (CEO) of Medidata, having played a key role in the success of the acquisition of Medidata in 2019, and his proven success as a business leader and visionary are a great complement to Medidata.

Michael Pray was named company COO. In his prior role as Medidata chief commercial officer, he was instrumental in the rapid growth of the company, which includes more than doubling total revenue to over US$1 billion and 100 per cent growth in number of customers during the last six years.

Pray will lead the day-to-day operations at Medidata, and will work closely with Daloz to build a complete solution set serving the life sciences industry at large.

“Customers are asking to do more with Medidata, and we are evolving to meet their digital transformation needs. Building on the strong foundation that has been set over the last 20 years, we will continue to pioneer unmatched solutions across the life sciences lifecycle,” said Daloz in a statement.

“We are extremely committed to this industry and will continue investing to achieve the vision that includes prevention to precision medicine and discovery to distribution, in order to be at the centre of every patient journey.”

Medidata, headquartered in New York City, is leading the digital transformation of life sciences, creating hope for millions of patients.

For more information, visit www.medidata.com.

-- BERNAMA

No comments:

Post a Comment